HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums

This article was originally published in The Rose Sheet

Executive Summary

Fragrance marketer will introduce fragrances and complementary products under the Van Cleef & Arpels brand name per a licensing agreement with the jewelry designer, Inter Parfums announces Oct. 4. The license will run for 12 years, and each party has the right to extend the term for five years on or before June 1, 2018 if certain sales targets are met, firm notes. The deal represents an important step in Inter Parfums development, according to Inter Parfums CEO Jean Madar. "We believe its growth potential will strengthen opportunities for expansion of our fragrance business in the high luxury segment," he says. Concurrently, Van Cleef & Arpels' most recent fragrance licensee, YSL Beaute, has signed an agreement for early termination of its contract with the jewelry brand, a move that will allow YSL to focus on core fragrances. Van Cleef & Arpels fragrances include First, Tsar and Van Cleef & Arpels...

You may also be interested in...



Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel